- Home
- STRO vs REFI Comparison
STRO vs REFI Comparison
Compare STRO & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | REFI |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.8M | 278.8M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STRO | REFI |
|---|---|---|
| Price | $16.12 | $10.76 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $31.33 | N/A |
| AVG Volume (30 Days) | ★ 288.8K | 168.4K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.79% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | $38,419,000.00 | ★ $48,857,628.00 |
| Revenue This Year | N/A | $17.47 |
| Revenue Next Year | N/A | $0.06 |
| P/E Ratio | ★ N/A | $18.70 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $9.69 |
| 52 Week High | $43.85 | $13.49 |
Technical Indicators
Market Signals| Indicator | STRO | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 33.08 | 46.92 |
| Support Level | $14.81 | $10.63 |
| Resistance Level | $17.33 | $10.97 |
| Average True Range (ATR) | 1.01 | 0.23 |
| MACD | 0.16 | -0.04 |
| Stochastic Oscillator | 39.11 | 21.33 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.